Impacts

TIA is set to boost our capabilities and resources following the announcement of NCRIS 2023 funding by The Hon Jason Clare MP, Minister for Education, and The

Momelotinib, a drug discovered by Australian researchers over several decades, has recently been approved by the US Food and Drug Administration (FDA) for the treatment

Chlamydia is infecting up to half of the koalas living in Queensland and New South Wales, causing blindness and infertility. Antibiotics exist, but they can

Research in eye, gum, heart and kidney disease, reproductive and developmental biology, cancer, infections, high blood pressure, therapeutic development, microbiome, immunity, endometriosis and osteoarthritis will

The Commonwealth Government’s Medical Research Future Fund (MRFF) National Critical Research Infrastructure Grant has invested $9.75 million into establishing MedChem Australia, a new national medicinal

Associate Professor Anthony Kicic leads a team at the Telethon Kids Institute towards a new way of fighting antimicrobial resistance (AMR). While he employs his

TIA has supported kidney disease research that is now underpinning the establishment of new Monash biotech company xCystence Bio. xCystence Bio has received funding to

Early-stage research projects in areas such as autoimmune disease, antimicrobial-resistant infections and eye disorders are benefiting from expert advice from TIA facilities to maximise their

TIA has supported a team from The University of Queensland that is now the biggest supplier of experimental mRNA vaccines and therapies in Australia, with